Company news

4D Molecular Therapeutics, Inc. news in 2025

4D Molecular Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease

December 17, 2025

4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 8, 2025

4DMT to Participate in 8th Annual Evercore Healthcare Conference

November 20, 2025

4DMT Appoints Kristian Humer as Chief Financial Officer

November 17, 2025

4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

November 10, 2025

4DMT to Participate in Jefferies 2025 London Healthcare Conference

November 6, 2025

4DMT Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants

November 6, 2025

4DMT Announces Positive Long-Term Data from Phase 1/2 PRISM Clinical Trial in Wet AMD Supporting 4D-150’s Potential as a Backbone Therapy with Consistent and Durable Benefit over Multiple Years

November 6, 2025

4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific

October 30, 2025

4DMT to Participate in Chardan's 9th Annual Genetic Medicines Conference

October 14, 2025

4DMT Advances 4D-710 to Phase 2 with Additional Funding and Support from the Cystic Fibrosis Foundation

October 13, 2025

4DMT Announces Leadership Expansion with Proven Late-Stage Executives to Drive 4D-150 Execution and BLA Readiness

September 2, 2025

4DMT to Participate in Upcoming Investor Conferences

August 25, 2025

4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

August 11, 2025

4DMT to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

August 6, 2025

4DMT Presents Positive 60-Week Results from 4D-150 SPECTRA Clinical Trial in DME and Regulatory Update

July 31, 2025

4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina Specialists

July 24, 2025

BBOT Appoints Industry Veteran Uneek Mehra as Chief Financial Officer

July 21, 2025

4DMT Announces Accelerated 4D-150 Phase 3 Development in Wet AMD and Streamlined Organization to Drive Late-Stage Execution

July 2, 2025

4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

May 8, 2025

4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DME

May 1, 2025

4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD

March 10, 2025

4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

February 28, 2025

4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program

February 7, 2025

4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population

January 28, 2025

4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway

January 9, 2025

4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational Path

January 9, 2025

Decks in 2025